- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
Total 5 results
-
Gustave Roussy, Cancer Campus, Grand ParisActive, not recruitingMetastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF MutationFrance
-
Centre Georges Francois LeclercRecruitingPatients With a Thyroid Tumor Who Received Radioactive Iodine TreatmentFrance
-
Ikena OncologyRecruitingColorectal Cancer | Pancreatic Cancer | Thyroid Carcinoma | Solid Tumor, Adult | Malignant Melanoma | Non-Small Cell Lung Carcinoma | BRAF Gene Mutation | Gliomas, Malignant | Ras (Kras or Nras) Gene Mutation | CRAF Gene MutationUnited States
-
Black Diamond Therapeutics, Inc.RecruitingMelanoma | Colorectal Cancer | NSCLC | Solid Tumor | Metastatic Lung Cancer | Metastatic Lung Non-Small Cell Carcinoma | Metastatic Melanoma | Non-small Cell Lung Cancer | Histiocytosis | Melanoma (Skin) | Recurrent Melanoma | Thyroid Carcinoma | Thyroid Cancer | Brain Metastases | Recurrent Histiocytic and Dendritic... and other conditionsUnited States
-
Novartis PharmaceuticalsRecruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationItaly, Spain, United States, France, Thailand, Malaysia, China, Germany, India, Turkey, Belgium, Argentina, Bulgaria, Netherlands, Hungary, Greece, Portugal, Austria, Singapore, Brazil, United Kingdom